02.11.2015 amp biosimilars AG  DE000A0SMU87

DGAP-News: amp biosimilars AG to present at German Equity Forum 2015


 
DGAP-News: amp biosimilars AG / Key word(s): Conference amp biosimilars AG to present at German Equity Forum 2015 02.11.2015 / 10:00 --------------------------------------------------------------------- amp biosimilars AG to present at German Equity Forum 2015 Hamburg, Germany, November 2, 2015 - amp biosimilars AG (ISIN: DE000A0SMU87), a company specializing in the development of high-quality biosimilars, today announced that it will be presenting for the first time at German Equity Forum being held 23 - 25 November 2015 in Frankfurt am Main, Germany. Dr. Marc W. Hentz, Chief Executive Officer, and Gunnar Janssen, Chief Financial Officer of amp biosimilars AG, will present at the conference on Monday, 23 November, in the Oslo room at 5.30 p.m. CET. The German Equity Forum is Europe's largest and most important capital market event for corporate finance and a central matching platform for senior company representatives from various industries and the financial community. It will take place from Monday to Wednesday, 23 to 25 November 2015, at the Sheraton Frankfurt Airport Hotel and Conference Center in Frankfurt. For more information about the event program, time frame and location, please see the event website, www.eigenkapitalforum.com. If you want to schedule an investor or a media meeting with amp biosimilars at this event, please e-mail us at: [email protected]. About amp biosimilars AG: amp biosimilars AG develops high quality biosimilars to meet growing demand on global therapeutic markets and is one of the most innovative and dynamic biosimilar companies in Europe. The company is headquartered in Hamburg and run by a team of leading industry experts. The development of a wide variety of biosimilars will provide patients around the world with access to life-improving and life-saving therapies. The combination of a research platform with state-of-the-art analytics, process technology and clinical expertise as well as regulatory know-how, makes amp biosimilars AG one of the leading companies for biosimilar development and marketing. Thanks to an international network of leading pharmaceutical companies, amp biosimilars AG also has direct access to the strongest growing markets in the world. With this approach amp biosimilars AG has a key position in one of the fastest growing life science markets in the near future. amp biosimilars AG has been listed on the Munich Stock Exchange since April 1, 2015. For more information please go to www.ampbiosimilars.com. Contact: MC Services AG Anne Hennecke T +49 211 529252-22 Email: [email protected] --------------------------------------------------------------------- 02.11.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- 407223 02.11.2015


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 0,05 2,55 10,13 16,38 189,86 193,29 70,00
EBITDA1,2 -0,68 -4,94 -4,67 -12,34 320,06 -58,12 -10,00
EBITDA-Marge3 -1.360,00 -193,73 -46,10 -75,34 168,58 -30,07
EBIT1,4 -0,68 -5,57 -8,57 -30,48 254,13 -265,35 -110,00
EBIT-Marge5 -1.360,00 -218,43 -84,60 -186,08 133,85 -137,28 -157,14
Jahresüberschuss1 -0,70 -5,60 -9,27 -84,26 287,16 -265,78 -125,00
Netto-Marge6 -1.400,00 -219,61 -91,51 -514,41 151,25 -137,50 -178,57
Cashflow1,7 -0,69 -4,97 -6,01 183,48 88,07 0,96 0,00
Ergebnis je Aktie8 -0,01 -0,10 -0,17 -1,58 5,37 -4,97 -1,10
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Liebhart & Kollegen

INVESTOR-INFORMATIONEN
©boersengefluester.de
Northern Data
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0SMU8 26,850 - 1.436,40
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
12,79 14,34 0,87 -76,71
KBV KCV KUV EV/EBITDA
4,00 1.496,25 7,43 -24,03
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,00 0,00 0,00 06.05.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
- 22.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-2,70% 12,06% 2,09% 134,09%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu amp biosimilars AG  ISIN: DE000A0SMU87 können Sie bei EQS abrufen


IT-Infrastruktur , A0SMU8 , NB2 , XETR:NB2